Principles Of Cancer Genetics by Fred BunzPrinciples Of Cancer Genetics by Fred Bunz

Principles Of Cancer Genetics

byFred Bunz

Hardcover | March 9, 2016

Pricing and Purchase Info

$95.96 online 
$151.95 list price save 36%
Earn 480 plum® points

Prices and offers may vary in store


Ships within 1-2 weeks

Ships free on orders over $25

Not available in stores


This is the second edition of a widely used textbook that consolidates the basic concepts of the cancer gene theory and provides a framework for understanding the genetic basis of cancer. Particular attention is devoted to the origins of the mutations that cause cancer, and the application of evolutionary theory to explain how the cell clones that harbor cancer genes tend to expand. Focused on the altered genes and pathways that cause the growth of the most common tumors,Principles of Cancer Geneticsis aimed at advanced undergraduates who have completed introductory coursework in genetics, biology and biochemistry, medical students and medical house staff. For students with a general interest in cancer, this book provides a highly accessible and readable overview. For more advanced students contemplating future study in the field of oncology and cancer research, this concise book will be useful as a primer.

Fred Bunz, M.D., Ph.D is a native of Long Beach, New York. He attended Stony Brook University and graduated from its Medical Scientist Training Program. His doctoral research in the enzymology of human DNA replication was conducted at Cold Spring Harbor Laboratory. Dr. Bunz completed a postdoctoral fellowship in Cancer Genetics at The ...
Title:Principles Of Cancer GeneticsFormat:HardcoverDimensions:343 pages, 23.5 × 15.5 × 0.03 inPublished:March 9, 2016Publisher:Springer-Verlag/Sci-Tech/TradeLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:940177482X

ISBN - 13:9789401774826

Look for similar items by category:


Table of Contents


Chapter 1: The Genetic Basis of Cancer

The cancer gene theory

Cancers are invasive tumors

Cancer is a unique type of genetic disease

What are cancer genes and how are they acquired?

Mutations alter the human genome

Genes and mutations

Single nucleotide substitutions

Gene silencing is marked by cytosine methylation: epigenetics

Environmental mutagens, mutations and cancer

Inflammation promotes the propagation of cancer genes

Stem cells, Darwinian selection and the clonal evolution of cancers

Selective pressure and adaptation: hypoxia and altered metabolism

Multiple somatic mutations punctuate clonal evolution

Tumor growth leads to cellular heterogeneity

Tumors are distinguished by their spectrum of driver gene mutations and passenger gene mutations

Colorectal cancer: a model for understanding the process of tumorigenesis

Do cancer cells divide more rapidly than normal cells?

Germline cancer genes allow neoplasia to bypass steps in clonal evolution

Cancer syndromes reveal rate-limiting steps in tumorigenesis

The etiolog

ic triad: heredity, the environment, and stem cell division

Understanding cancer genetics

Chapter 2: Oncogenes

What is an oncogene?

The discovery of transmissible cancer genes

Viral oncogenes are derived from the host genome

The search for activated oncogene

s: the RAS gene family

Complex genomic rearrangements: the MYC gene family

Proto-oncogene activation by gene amplification

Proto-oncogenes can be activated by chromosomal translocation

Chromosomal translocations in liquid tumors

Chronic myeloid leukemia and the Philadelphia chromosome

Oncogenic activation of transcription factors in Prostate cancer and Ewing's sarcoma

Oncogene discovery in the genomic era: mutations inPIK3CA

Selection of tumor-associated mutations

Multiple modes of proto-oncogene activation

Oncogenes are dominant cancer genes

Germline mutations inRETandMETconfer cancer predisposition

Proto-oncogene activation and tumorigenesis

Chapter 3: Tumor Suppressor Genes

What is a tumor suppressor gene?

The discovery of recessive cancer phenotypes

Retinoblastoma and Knudson's two-hit hypothesis

Chromosomal localization of the retinoblastoma gene

The mapping and cloning of the retinoblastoma gene

Tumor suppressor gene inactivation: the second 'hit' and loss of heterozygosity

Recessive genes, dominant traits

APCinactivation in inherited and sporadic colorectal cancers

TP53inactivation: a frequent event in tumorigenesis

Functional inactivation of p53: tumor suppressor genes and oncogenes interact

MutantTP53in the germl

ine: L

i Fraum

eni syn



ins-of-function caused by cancer-associated mutations inTP53

Cancer predisposition: allelic penetrance, relative risk and the odds ratio

Breast cancer susceptibility:BRCA1andBRCA2

Genetic losses on chromosome 9:CDKN2A

Complexity atCDKN2A: neighboring and overlapping genes

Genetic losses on chromosome 10:PTEN

SMAD4and the maintenance of stromal architecture

Two distinct genes cause neurofibromatosis

From flies to humans, Patched proteins regulate developmental morphogenesis

von Hippel-Lindau disease

NOTCH1: tumor suppressor gene or oncogene?

Multiple endocrine neoplasia type 1

Most tumor suppressor genes are tissue-specific

Modeling cancer syndromes in mice

Genetic variation and germline cancer genes

Tumor suppressor gene inactivation during colorectal tumorigenesis

Inherited tumor suppressor gene mutations: gatekeepers and landscapers

Maintaining the genome: caretakers

Chapter 4: Genetic Instability and Cancer

What is genetic instability?

The majority of cancer cells are aneuploid

Aneuploid cancer cells exhibit chromosome instability

Chromosome instability arises early in colorectal tumorigenesis

Chromosomal instability accelerates clonal evolution

Aneuploidy can result from mutations th

at directly im

pact mitosis



the cohesion

of sister chromatids

Other genetic and epigenetic causes of aneuploidy

Transition from tetraploidy to aneuploidy during tumorigenesis

Multiple forms of genetic instability in cancer

Defects in mismatch repair cause hereditary nonpolyposis colorectal cancer

Mismatch repair-deficient cancers have a distinct spectrum of mutations

Defects in nucleotide excision repair cause xeroderma pigmentosum

NER syndromes: clinical heterogeneity and pleiotropy

DNA repair defects and mutagens define two steps towards genetic instability

Defects in DNA crosslink repair cause Fanconi anemia

A defect in DNA double strand break responses causes ataxia-telangiectasia

A unique form of genetic instability underlies Bloom syndrome

Aging and cancer: insights from the progeroid syndromes

Instability at the end: telomeres and telomerase

Overview: genes and genetic stability

Chapter 5: Cancer Genomes

Discovering the genetic basis of cancer: from genes to genomes

What types of genetic alterations are found in tumor cells?

How many genes are mutated in the various types of cancer?

What is the significance of the mutations that are found in cancers?

When do cancer-associated mutations occur?

How many different cancer genes are there?

How many cancer gene

s are required for th

e development

of cancer?


r genetics sha

pes our understanding

of metastasis

Tumors are genetically heterogenous

Beyond the exome: the 'dark matter' of the cancer genome

A summary: the genome of a cancer cell

Chapter 6: Cancer Gene Pathways

What are cancer gene pathways?

Cellular pathways are defined by protein-protein interactions

Individual biochemical reactions, multistep pathways, and networks

Protein phosphorylation is a common regulatory mechanism

Signals from the cell surface: protein tyrosine kinases

Membrane-associated GTPases: the RAS pathway

An intracellular kinase cascade: the MAPK pathway

Genetic alterations of the RAS pathway in cancer

Membrane-associated lipid phosphorylation: the PI3K/AKT pathway

Control of cell growth and energetics: the mTOR pathway

Genetic alterations in the PI3K/AKT and mTOR pathways define roles in cell survival

The STAT pathway transmits cytokine signals to the cell nucleus

Morphogenesis and cancer: the WNT/APC pathway

Dysregulation of the WNT/APC pathway in cancers

Notch signaling mediates cell-to-cell communication

Morphogenesis and cancer: the Hedgehog pathway

TGF- / SMAD signaling maintains adult tissue homeostasis

MYC is a downstream effector of multiple cancer gene pathways

activation is triggere

d by damaged or incompletely

replicated chromosom


p53 is controlled b

y protein kinases enc

oded by

tumor suppressor genes

p53 induces the transcription of genes that suppress cancer phenotypes

Feedback loops dynamically control p53 abundance

The DNA damage signaling network activates interconnected repair pathways

Inactivation of the pathways to apoptosis in cancer

RB1 and the regulation of the cell cycle

Several cancer gene pathways converge on cell cycle regulators

Many cancer cells are cell cycle checkpoint-deficient

Chromatin modification is recurrently altered in many types of cancer

Summary: putting together the puzzle

Chapter 7: Genetic Alternations in Common Cancers

Cancer genes cause diverse diseases

Cancer incidence and prevalence

Lung cancer

Prostate cancer

Breast cancer

Colorectal cancer

Endometrial cancer

Melanoma of the skin

Bladder cancer


Cancers in the kidney

Thyroid cancer


Cancer in the pancreas

Ovarian cancer

Cancers of the oral cavity and pharynx

Liver cancer

Cancer of the uterine cervix

Stomach cancer

Brain tumors

Chapter 8: Cancer Genetics in the Clinic

The uses of genetic information

Elements of cancer risk: carcinogens and genes

Identifying carriers o

f germline cancer genes


r genes as biomarkers of ear

ly stage malignancies


genes as biomarkers f

or diagnosis, prognosis and recurrence

Conventional anticancer therapies inhibit cell growth

Exploiting the loss of DNA repair pathways: synthetic lethality

On the horizon: achieving synthetic lethality inTP53-mutant cancers

Molecularly targeted therapy:BCR-ABLand imatinib

Clonal evolution of therapeutic resistance


Antibody-mediated inhibition of receptor tyrosine kinases

Inhibiting Hedgehog signaling

A pipeline from genetically-defined targets to targeted therapies

Neoantigens are recognized by the immune system

The future of oncology